In pancreatic ductal adenocarcinoma (PDAC), SMAD4 mutations are particularly prevalent, occurring in ∼50% of cases, and are strongly associated with shorter survival and poor prognosis. Here, SMAD4 is linked to pancreatic ductal adenocarcinoma.